261 related articles for article (PubMed ID: 29766829)
1. Acute Myeloid Leukemia: Diagnosis and Management Based on Current Molecular Genetics Approach.
Suguna E; Farhana R; Kanimozhi E; Kumar PS; Kumaramanickavel G; Kumar CS
Cardiovasc Hematol Disord Drug Targets; 2018; 18(3):199-207. PubMed ID: 29766829
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature.
Assaf N; El-Cheikh J; Bazarbachi A; Salem Z; Farra C; Chakhachiro Z; Nassif S; Zaatari G; Mahfouz R
Mol Biol Rep; 2019 Apr; 46(2):2003-2011. PubMed ID: 30701458
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
4. Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia.
Forthun RB; Aasebø E; Rasinger JD; Bedringaas SL; Berven F; Selheim F; Bruserud Ø; Gjertsen BT
J Proteomics; 2018 Feb; 173():32-41. PubMed ID: 29175091
[TBL] [Abstract][Full Text] [Related]
5. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
6. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B
Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614
[TBL] [Abstract][Full Text] [Related]
7. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
8. Importance of assessing cytogenetic and molecular risk factors in acute myeloid leukemia therapy.
Coles EC; Colita A; Momanu R; Berbec N; Ivanescu AM; Oprea M; Jardan D; Jardan C; Arghir A; Coriu D; Lupu AR
J Med Life; 2012; 5(Spec Issue):36-43. PubMed ID: 31803284
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
10. Subtype-specific patterns of molecular mutations in acute myeloid leukemia.
Rose D; Haferlach T; Schnittger S; Perglerová K; Kern W; Haferlach C
Leukemia; 2017 Jan; 31(1):11-17. PubMed ID: 27285584
[TBL] [Abstract][Full Text] [Related]
11. Bioinformatics Analysis to Determine Prognostic Mutations of 72 de novo Acute Myeloid Leukemia Cases from the Cancer Genome Atlas (TCGA) with 23 Most Common Mutations and no Abnormal Cytogenetics.
Welsh KJ; Nedelcu E; Wahed A; Bai Y; Dasgupta A; Nguyen A
Ann Clin Lab Sci; 2015; 45(5):515-21. PubMed ID: 26586702
[TBL] [Abstract][Full Text] [Related]
12. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
[TBL] [Abstract][Full Text] [Related]
13. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Molecular Markers in AML Patients: A Hospital-Based Study in Lebanon.
El Halabi L; Djaffar-Jureidini I; Hakime N; Saidy G; Chamseddine N
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S80-4. PubMed ID: 26297285
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
[TBL] [Abstract][Full Text] [Related]
16. [Genetic abnormalities in AML].
Nakajima H
Rinsho Ketsueki; 2019; 60(6):584-593. PubMed ID: 31281149
[TBL] [Abstract][Full Text] [Related]
17. Analysis of class I and II aberrations in Iraqi childhood acute myeloid leukemia using filter paper cards.
Al-Kzayer LF; Uyen le TN; Al-Jadiry MF; Al-Hadad SA; Al-Badri SA; Ghali HH; Ameen NA; Liu T; Matsuda K; Abdulkadhim JM; Al-Shujairi TA; Matti ZI; Hasan JG; Al-Abdullah HM; Al-Ani MH; Saber PA; Khalil HM; Inoshita T; Kamata M; Koike K; Sakashita K
Ann Hematol; 2014 Jun; 93(6):949-55. PubMed ID: 24464319
[TBL] [Abstract][Full Text] [Related]
18. A novel hierarchical prognostic model of AML solely based on molecular mutations.
Grossmann V; Schnittger S; Kohlmann A; Eder C; Roller A; Dicker F; Schmid C; Wendtner CM; Staib P; Serve H; Kreuzer KA; Kern W; Haferlach T; Haferlach C
Blood; 2012 Oct; 120(15):2963-72. PubMed ID: 22915647
[TBL] [Abstract][Full Text] [Related]
19. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
[TBL] [Abstract][Full Text] [Related]
20. NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia.
Su L; Gao SJ; Li W; Tan YH; Cui JW; Hu RP
Hematology; 2014 Sep; 19(6):324-8. PubMed ID: 24164801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
